Education
About Us
Working with TipRanks
Follow Us
Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
IVBXF Stock Chart & Stats
$11.00
$0.00(0.00%)
At close: 4:00 PM EST
$11.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.58 - $15.12
Previous CloseN/A
Volume2.00
Average Volume (3M)1.73K
Market Cap
$19.78B
Enterprise Value$131.87B
Total Cash (Recent Filing)$9.54B
Total Debt (Recent Filing)$3.38B
Price to Earnings (P/E)115.4
Beta-0.26
Next Earnings
Apr 01, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding1,735,186,000
10 Day Avg. Volume1,822
30 Day Avg. Volume1,733
Financial Highlights & Ratios
PEG Ratio6.48
Price to Book (P/B)4.26
Price to Sales (P/S)5.94
P/FCF Ratio-133.71
Enterprise Value/Market Cap6.67
Enterprise Value/Revenue11.54
Enterprise Value/Gross Profit15.12
Enterprise Value/Ebitda199.53
Forecast
1Y Price Target
$15.64Price Target Upside42.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth demonstrates strong commercial traction for approved biologics and expanding market penetration in China. Durable top-line expansion can support scale economies, fund R&D and commercialization activities internally, and improve negotiating leverage with payers and partners.
High Gross MarginA 74.4% gross margin indicates efficient biologics production and favorable product mix or pricing power. High product-level margins provide a structural buffer to absorb R&D and SG&A spend, improving the company’s ability to progress pipeline assets without immediate margin erosion.
Conservative Capital StructureLow leverage and a strong equity position reduce refinancing and interest-rate risks, offering financial flexibility to fund clinical programs and commercialization. This balance-sheet strength supports long-term investments and cushions the company during R&D cycles or market stress.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow limits the company’s ability to self-fund development and commercialization, forcing reliance on cash reserves or external financing. Over the medium term this can raise dilution risk, increase financing costs, and constrain strategic optionality.
Ongoing LossesContinued negative profitability despite revenue growth signals structural cost or scale issues. If operating losses persist, the firm may struggle to convert top-line strength into sustainable free cash flow, making long-term viability dependent on narrowing operating deficits.
Pipeline Concentration RiskFuture growth relies heavily on clinical and regulatory success of pipeline assets. Clinical trials and approvals are long, costly, and binary; setbacks or delays materially affect future revenues and cash generation, making long-term performance contingent on uncertain development outcomes.
Innovent Biologics News
IVBXF FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was $4.58 and its highest was $15.12 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $19.78B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Apr 01, 2026 which is in 38 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 27, 2025. The company reported $0.074 earnings per share for the quarter, beating the consensus estimate of $0.026 by $0.048.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.02.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,735,186,000 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of $0.074 in its last earnings report, beating expectations of $0.026. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in IVBXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.57%
12-Months-Change
Fundamentals
Return on Equity
8.41%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
IVBXF Stock 12 Month Forecast
Average Price Target
$15.64
▲(42.18% Upside)
Technical Analysis
Sino Biopharmaceutical
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
8.46% Mutual Funds
― Other Institutional Investors
82.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---